Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience

Alice Levard1, Olfa Derbel1, Pierre Méeus2, Dominique Ranchère3, Isabelle Ray-Coquard1, Jean-Yves Blay1 and Philippe A Cassier14*

Author Affiliations

1 Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec, 69008, Lyon, France

2 Department of Surgical Oncology, Centre Léon Bérard, 28 rue Laennec, 69008, Lyon, France

3 Department of Anatomopathology, Centre Léon Bérard, 28 rue Laennec, 69008, Lyon, France

4 Department of Medical Oncology, Centre Léon Bérard, Lyon, France

For all author emails, please log on.

BMC Cancer 2013, 13:109  doi:10.1186/1471-2407-13-109

Published: 11 March 2013

Abstract

Background

Solitary Fibrous Tumor is a rare type of soft tissue tumor of intermediate malignant potential which may recur or metastasize in 15-20% of cases. Data on the management of patients with advanced SFT is scarce: chemotherapy has been described as ineffective, while recent data suggests that anti-angiogenic therapies may be more efficient.

Methods

We conducted a retrospective study on patients treated for advanced SFT at a single institution: from January 1994 to December 2011, 30 patients were treated in the Centre Léon Bérard for an advanced SFT.

Results

Twenty-three patients received cytotoxic chemotherapy as first-line therapy. Best responses were 2 (9%) partial responses, 13 (57%) stable diseases (SD) and 8 (35%) progressive diseases (PD). Median Progression Free Survival (PFS) was 5.2 (95% CI: 3.2-7.1) months and 9 patients were free of progression at 6 months. Ten patients received an anti-angiogenic treatment (sunitinib or pazopanib) as a 2nd, 3rd or 4th line. Best responses were 5 SD and 5 PD; median PFS was 5.1 months (95% CI 0.7-9.6). Four patients (36%) were progression-free for more than 6 months. Two patients receiving pazopanib were without progression at 6 and 8 months and two patients receiving sunitinib were free of progression at 30 months.

Conclusion

Response rate with standard chemotherapy was low and PFS appear similar between cytotoxic chemotherapy and anti-angiogenic agents.